Positioning no disclosures inside 60 days, left as found
Options put/call open interest 2.99, read 2026-11-03
Ethical does not pass the values gate
Price1,224.37 USD
Fair value1,161.19
Ethical score10.0/100
Value readFairas of 4 Nov 2026
Our investment reviews on this name
2026-11-04Read Markup1,161.32+5.4% to today ✓Accumulation gives way to Markup first Markup read since October
2026-10-28Read Accumulation1,120.78+9.2% to today ✓Markup gives way to Accumulation first Accumulation read since October
2026-10-21Read Markup1,120.78+9.2% to today ✓Accumulation gives way to Markup first Markup read since August
2026-10-11Read Accumulation1,086.31+12.7% to today ✓Markdown gives way to Accumulation with results news in the headlines
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
BlackRock holds its Markup at $1,224.37. The statistical read favours the buyers, held for 12 days.
As held on the ledger · 2026-11-04
Phase
Markup
Quantitative state
The statistical read favours the buyers, held for 12 days
Price at the screen
$1,224.37
Valuation
26.78 trailing · 18.14 forward price to earnings
Values screen
FAIL· score 10.0
Beta
1.42
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Financials sector
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
BlackRock does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when BLK's ethical verdict changes
Today BLK does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Fair vs our fair value, as of 4 Nov 2026: 19.10% revenue growth.
Fair value range in USD, drawn from the 2026-11-04 screen. The gold marker is the market price at the same screen. The price runs 5.4% above the base estimate.
Third-party analyst targets: 17 covering, consensus Strong Buy. The average target sits +10% from the screen price.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $1,161.19, with a range of $1,125.00 to $1,335.37, dated to the 2026-11-04 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
An Asset Giant Struggling with Ethics
Imagine a world where every dollar in investment has a ripple effect, shaping economies and lives - this is BlackRock's domain. As the world's largest asset manager, BlackRock orchestrates trillions, influencing global finance through its vast portfolio. Yet, despite its market sway, the firm falls short on ethical grounds, failing our ethical screen due to certain questionable business activities.
Why it stands out - on paper. With a robust revenue growth of 31%, a healthy profit margin of 24%, and a ROE of 12%, BlackRock's financial metrics would typically make it an attractive proposition for investors seeking both growth and stability. Its forward P/E of 17.8x aligns closely with our fair valuation, suggesting the market's current pricing is neither over nor underestimating its potential.
However, despite the attractive financials, we must pass on BlackRock. The firm's failure on our ethical screen is a significant red flag for an industry that holds so much power over societal wellbeing. While the consensus rating from analysts is a 'buy' with a median target suggesting a potential upside, the ethical considerations cannot be overlooked. This is a stark reminder that financial performance and ethical standards do not always go hand in hand. Analysis, not advice.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it already moves more than the market on an average day.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
BLK trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Markup · changed$1,161.32+3.6%Entry 15
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251.
2026-10-21Markup · changed$1,120.78+3.5%Entry 13
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 3.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 5% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251.
2026-10-14Accumulation$1,082.39+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-13Accumulation$1,082.39+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-12Accumulation$1,082.39-0.4%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-10Markdown · changed$1,086.31+0.0%Entry 8
The framework has shifted from distribution to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 4.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251.
2026-08-23Markup$1,139.82+6.3%Entry 6
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.3% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (16 analysts) rates it buy, with a mean price target of $1251.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.